Advertising Standards Authority Bans Gemma Collins Weight-Loss Drug Ad

The Advertising Standards Authority (ASA) has banned nine adverts, including a promoted Instagram post by television personality Gemma Collins, for illegally advertising prescription-only weight-loss medications to the public. The ASA’s crackdown, aimed at protecting consumers from unregulated promotion of prescription medicines, concluded that the posts breached advertising rules by encouraging public requests for medications that require medical oversight in the UK.

Gemma Collins’ Instagram Post Among Banned Advertisements

On 6 January 2024, Gemma Collins shared an Instagram video endorsing Yazen, a Swedish digital healthcare provider offering a doctor-supervised weight-loss programme that combines prescription drugs with lifestyle coaching. Collins stated in the video, “I’m starting this year two sizes down, thanks to Yazen’s weight loss app and medication,” adding, “I’m not telling anyone to go on this medication, but it is prescribed on the NHS.”

Despite the lack of explicit naming of a specific prescription drug in her post, the ASA ruled that the advertisement nonetheless promoted prescription-only weight-loss medications, which is illegal in the UK without proper regulatory approval. The Medicines and Healthcare products Regulatory Agency (MHRA), which the ASA consulted, expressed concern that the advert was likely to encourage consumers to seek prescriptions for weight-loss drugs, contravening marketing laws.

In response to the ruling, Collins acknowledged that her post promoted the Yazen service and stated she would adhere to advertising guidelines going forward.

Broader Crackdown on Prescription Weight-Loss Drug Advertising

Alongside Collins’ Instagram post, the ASA prohibited eight other adverts on platforms including Meta (Facebook/Instagram) and Google. These adverts promoted digital clinics and online pharmacies advertising prescription-only weight loss treatments such as GLP-1 receptor agonists, often administered by injection. The banned adverts included:

• CheqUp Health’s paid Meta ad encouraging “sustainable weight loss.”
• HealthExpress.co.uk’s Meta ad featuring a partial image of an injection pen.
• Juniper UK’s Google search ad promoting “GLP-1 Weekly Weight Loss Injection.”
• Phlo Clinic’s Google ads offering discounts and promoting “weight loss injections.”
• SemaPen’s Google ad stating “SemaPen Makes Weight Loss Easier.”
• Cloud Pharmacy’s Meta ad showing text conversations about new weight-loss medications available online.
• pharmacyonline.co.uk’s Google ad featuring “Obesity Treatment Jab” imagery.

The ASA’s judgment emphasized that such adverts create misleading impressions that prescription drugs can be purchased and used without medical supervision, contrary to UK medicines law. The regulator mandated removal or amendment of these ads to prevent further consumer harm.

Regulatory Context and Health Risks

Prescription-only weight-loss medications typically include GLP-1 receptor agonists such as semaglutide and liraglutide. These drugs require clinical assessment and ongoing medical supervision due to potential side effects and contraindications. The UK’s MHRA regulates prescription medicines to ensure safe clinical use, and direct-to-consumer advertising of such medicines is strictly controlled to prevent misuse.

Dr. Sarah Williams, a clinical pharmacologist at the University of London, explained: “These medications can be highly effective but are not suitable for everyone. Unsupervised use can lead to adverse effects. Advertising them to the general public risks patients self-prescribing or pressuring doctors for inappropriate treatments.”

The rise of online healthcare platforms offering ‘telemedicine’ weight-loss programmes has accelerated since the COVID-19 pandemic, expanding access but also raising regulatory challenges. Digital clinics prescribe medications after virtual consultations, but strict rules govern how these services advertise.

Celebrity Influence and the Risks of Social Media Endorsements

Gemma Collins is one of several influencers whose endorsements of health-related products reach millions. Such promotions can impact public decision-making significantly, particularly when they involve medical treatments.

Advertising expert Helen Carter from the Advertising Standards Authority stated: “Celebrity endorsements carry significant persuasive power. It is vital they comply with advertising codes to protect consumers from misleading health claims, especially involving prescription medications.”

The ASA’s recent actions underscore the growing scrutiny of social media advertising practices. The Authority urges influencers and advertisers to ensure transparency and compliance, especially for health products with potentially serious implications.

Implications for Consumers and Industry

This enforcement sends a clear message: unregulated promotion of prescription-only medicines is illegal and poses risks. Consumers are advised to seek medical advice before starting any weight-loss medication or programme.

Dr. Jennifer Miles, an NHS obesity specialist, remarked, “Sustainable weight management typically involves a combination of dietary changes, physical activity, and sometimes medication or surgery under medical supervision. Quick fixes advertised online may not be safe or effective.”

The digital health sector faces increased regulatory oversight as appetite grows for telemedicine weight-loss services. Companies must balance marketing ambitions with legal and ethical responsibilities.

Looking Ahead: Regulatory and Industry Trends

The UK government and regulators continue to update guidelines to adapt to digital marketing’s evolving landscape. The ASA has indicated ongoing monitoring of online health advertisements and readiness to act against breaches.

Meanwhile, health advocates emphasize the importance of public education about safe weight loss methods. Campaigns promoting healthy lifestyle changes, combined with responsible medical care, remain central to addressing obesity, which affects over 28% of UK adults according to Public Health England.

As celebrity endorsements and digital ads proliferate, ensuring regulatory compliance will be critical to safeguarding public health and maintaining trust.

Summary

The ban on nine Instagram, Facebook, and Google adverts promoting prescription-only weight-loss drugs including a Gemma Collins post reflects the UK regulators’ commitment to enforcing strict controls over health-related advertising. These measures aim to protect consumers from misleading medical claims and unregulated access to prescription medications online.

For more detailed analysis and ongoing coverage of US labor markets, trade policies, UK government, finances and markets stay tuned to  PGN Business Insider.